Overview

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Status:
Active, not recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

This is a non-randomized, open-label, Phase IbI study to assess the safety and efficacy of oral decitabine (ASTX727) and durvalumab (MEDI4736) combination therapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have progressed during or after treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy for recurrent and/or metastatic disease. The clinical trial is studying drugs that can boost the participant's immune system against the cancer cells as a possible treatment for head and neck cancer. The study interventions involved in this study are: - Oral Decitabine (ASTX 727) - Durvalumab (MEDI4736)

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborators:

Astex Pharmaceuticals, Inc.
AstraZeneca

Treatments:

Antibodies, Monoclonal
Azacitidine
Decitabine
Durvalumab
Tremelimumab